On May 6th, 2020, the Food and Drug Administration (FDA) approved Tabrecta (capmatinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET. The FDA based their approval on the results of the clinical trial [...]
On March 27, 2020, the Food and Drug Administration (FDA) approved Imfinzi (durvalumab) in combination with etoposide and either carboplatin or cisplatin as first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The FDA based their [...]
On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no [...]
On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor [...]
The GO2 for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care” – individuals and organizations that advance [...]
Last year was an exciting year for lung cancer research with more U.S. Food and Drug Administration (FDA) approval decisions relevant to lung cancer than ever before. So, what can we expect for 2019? Another eventful year with researchers [...]
The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK [...]